Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Immunology Miniatures

Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma

Christopher A. Barker, Michael A. Postow, Shaheer A. Khan, Kathryn Beal, Preeti K. Parhar, Yoshiya Yamada, Nancy Y. Lee and Jedd D. Wolchok
Christopher A. Barker
Authors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Postow
Authors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaheer A. Khan
Authors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn Beal
Authors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Preeti K. Parhar
Authors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiya Yamada
Authors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Y. Lee
Authors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jedd D. Wolchok
Authors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New YorkAuthors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New YorkAuthors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New YorkAuthors' Affiliations: Department of Radiation Oncology, Melanoma and Sarcoma Service, Department of Medicine, Ludwig Institute for Cancer Research, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; and Weill Cornell Medical College, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6066.CIR-13-0082
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Ipilimumab and radiotherapy are commonly used to treat unresectable and metastatic melanoma. Results from preclinical studies and case reports suggest a biologic interaction between these two treatments. To understand the clinical implications of the interaction, we carried out a retrospective study reviewing records of patients treated with ipilimumab and radiotherapy for melanoma at our institution between 2005 and 2011. The review included details of treatment, response, adverse events (AE), and overall survival (OS). Twenty-nine patients underwent 33 courses of non-brain radiotherapy between their first and last dose of ipilimumab. Immune-related AEs (ir-AEs) were observed in 43% of patients receiving ipilimumab at 10 mg/kg and in 22% of patients receiving 3 mg/kg; the frequency of ir-AEs was not significantly different compared with previous studies of ipilimumab alone. Radiotherapy-related AEs were significantly more common in patients receiving higher doses of radiation. Palliation of symptoms was reported by 77% of patients after radiotherapy. Median OS was 9 and 39 months in patients receiving radiotherapy during induction and maintenance with ipilimumab, respectively. In this retrospective study, concurrent ipilimumab and radiotherapy was neither associated with higher than expected rates of AEs nor did it abrogate palliative effects of radiotherapy or survival benefits of ipilimumab. Further studies to prospectively explore the efficacy of this therapeutic combination are warranted. Cancer Immunol Res; 1(2); 1–7. ©2013 AACR.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Immunology Research Online (http://cancerimmunolres.aacrjournals.org/).

  • Received June 21, 2013.
  • Accepted June 27, 2013.
  • ©2013 American Association for Cancer Research.
Next
Back to top

Published OnlineFirst July 25, 2013
doi: 10.1158/2326-6066.CIR-13-0082

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
Citation Tools
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Christopher A. Barker, Michael A. Postow, Shaheer A. Khan, Kathryn Beal, Preeti K. Parhar, Yoshiya Yamada, Nancy Y. Lee and Jedd D. Wolchok
Cancer Immunol Res July 25 2013 DOI: 10.1158/2326-6066.CIR-13-0082

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
Christopher A. Barker, Michael A. Postow, Shaheer A. Khan, Kathryn Beal, Preeti K. Parhar, Yoshiya Yamada, Nancy Y. Lee and Jedd D. Wolchok
Cancer Immunol Res July 25 2013 DOI: 10.1158/2326-6066.CIR-13-0082
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The First Pipeline for Validating Personalized Neoantigens
  • Anti–PD-1 Pneumonitis and Persistent Imaging Abnormalities
  • Immunopathologic Stratification of Colorectal Cancer
Show more Cancer Immunology Miniatures
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement